astrazeneca glp-1 AstraZeneca's Elecoglipron Advances in Oral Market | Alan Nafiev posted on the topic Encouraging trial results for AstraZeneca's

The two are presented as working on different pathways: fat mobilization versus intake reduction

However, the optic nerve may be uniquely vulnerable to changes in perfusion, autoregulation, metabolic status and local anatomic susceptibility, and favorable systemic vascular effects may not necessarily translate into reduced optic nerve ischemic risk. Beyond their cardiovascular benefits, GLP-1 agents may also influence ocular microvascular physiology

Conversely, downregulated DEGs were enriched in BP categories related to synapse organization, extracellular matrix organization, and extracellular structure organization

Additionally, further research is needed to evaluate the exact role of AOX therapy and to identify the most effective single AOX or AOX combinations in these conditions

Besides this purely quantitative aspect, Frye et al[39] analyzed the acyl-carnitine profile of ASD patients, in a large cohort ( n = 213), these authors reported that 17% of children with ASD exhibited an elevation in short-chain and long-chain, but not medium-chain, acyl-carnitines